200002102-2
IPOS reference

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 33/14, 31/715 — A1

(11) International Publication Number: WO 99/22746

(43) International Publication Date: 14 May 1999 (14.05.99)

(21) International Application Number: PCT/US97/19964

(22) International Filing Date: 31 October 1997 (31.10.97)

(71) Applicant *(for all designated States except US)*: BIOTIME, INC. [US/US]; 935 Pardee Street, Berkeley, CA 94710 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: SEGALL, Paul, E. [US/US]; 935 Pardee Street, Berkeley, CA 94710 (US). STERNBERG, Hal [US/US]; 935 Pardee Street, Berkeley, CA 94710 (US). WAITZ, Harold, D. [US/US]; 935 Pardee Street, Berkeley, CA 94710 (US). SEGALL, Judith, M. [US/US]; 935 Pardee Street, Berkeley, CA 94710 (US).

(74) Agents: FIELD, Bret, E. et al.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: PHYSIOLOGICALLY ACCEPTABLE AQUEOUS SOLUTIONS AND METHODS FOR THEIR USE

(57) Abstract

Physiologically acceptable aqueous solutions and methods for their use are provided. The subject solutions comprise: electrolytes; a dymamic buffering system and an oncotic agent; and do not comprise a conventional biological buffer. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute.